At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
LBH589drug
Likely dose
LBH589 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of LBH589 in Patients With Metastatic Medullary Thyroid Cancer and Radioactive Iodine Resistant Differentiated Thyroid Cancer
In Brief
A Phase 2 clinical trial evaluating LBH589 for Thyroid Carcinoma. Completed, enrolled 13 participants across 3 sites.
Detailed Summary
The purpose of this study is to evaluate the tumor response rate in patients with metastatic medullary thyroid cancer (MTC) or radioiodine resistant differentiated thyroid cancer (DTC) after receiving treatment with LBH589 20 mg by mouth, three times weekly. Time to progression, overall survival, toxicity, tolerability, and Notch1 protein expression patterns will also be evaluated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThyroid Carcinoma
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2009
Enrollment StartJan 2010
Primary CompletionAug 2013
Study CompletionFeb 2016
TodayJul 2026
First PostedNov 13, 2009
Enrollment StartJan 1, 2010
Primary CompletionAug 1, 2013
Study CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 16.6 years ago
Interventions
LBH589drug
LBH589 20mg by mouth three times weekly (Monday/Wednesday/Friday) for 28-day cycles.